Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials

doi:10.5306/wjco.v13.i5.388

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7764)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

506

WORD

143

HTML

4575

Figures (1-1)

281

Tables (1-2)

456

Sum=5961

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

262

Download

702

Sum=964

Publishing Process of This Article

Item

Count

Browse

321

Download

518

Sum=839

May 24, 2022 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Clin Oncol. May 24, 2022; 13(5): 388-411
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.388

Full Size Figure Download Figure

Figure 1 Article selection flow diagram. RCTs: Randomized controlled trials.

Citation: Poulose JV, Kainickal CT. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. World J Clin Oncol 2022; 13(5): 388-411
URL: https://www.wjgnet.com/2218-4333/full/v13/i5/388.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i5.388